ECE2017 Eposter Presentations: Diabetes, Obesity and Metabolism Obesity (81 abstracts)
Intensified telematic treatment for obesity using the web platform PREDIRCAM2, descriptive basal characteristics and preliminary results
Valeria Alcantara-Aragon 1 , Susana Rodrigo-Cano 2, , Maria José Martínez 1 , Carmen Martínez 1 , José Tapia 3, , José Iniesta 3, , Ascension Lupiañez 1 , Susana Tenés 2, , M Elena Hernando 3, , J Francisco Merino-Torres 2, , Alberto de Leiva 1, & Cintia Gonzalez 1,
1Endocrinology and Nutrition Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 2Endocrinology and Nutrition Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; 3Telemedicine and Bioengineering Group, Universidad Politécnica de Madrid, Madrid, Spain; 4Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), and Eduab-HSP Group, Universitat Autònoma de Barcelona, Barcelona, Spain; 5Unidad Mixta de Investigación Endocrinología, Nutrición y Dietética. Instituto Investigación Sanitaria La Fe-Universitat de Valencia, Valencia, Spain; 6Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
Background: PREDIRCAM2 is a web platform for obesity treatment and follow-up. It contains modules for: dietary prescription and registry with nutritional analysis based on individualized and mediterranean dietary goals, physical activity prescription and tracking with individualized targets, and anthropometric tracking. An ongoing multicenter randomized clinical trial evaluates the intervention’s effectiveness in obesity treatment and cardio-metabolic-risk prevention.
Methods: Inclusion criteria: 18–65 years-old, BMI 30–39.9 kg/m2, no medication for type-2 Diabetes Mellitus (DM), dyslipidemia (DLP) or hypertension (HT). Randomization to intensified technological intervention (TI) supported by PREDIRCAM2 platform, or traditional non-technological face-to-face intensified treatment intervention (NTI). Both groups receive one year follow-up through 12 appointments with health-care professionals, 4 of which are exclusively telematic in the TI group.
Basal characteristics: 183 participants have been included, BMI 34.74±2.74, age 44.27±10.62, 84% female (31% postmenopausal, 6.5% history of gestational DM), 54% high education level, 54% married. Comorbidities: 2.2% type-2 DM, 5.5% HT, 11.5% DLP, 6.5% Depression, 2.7% diagnosed eating disorders. 56% received medication, most frequently antidepressants (24.5%) followed by vitamin D supplements (11.8%). 68% reported anxiety towards food, overeating in the form of: pecking 84.7%, binge-eating 35.5%, binge-and-vomiting 3.2%.
Preliminary results: 119 participants have completed 3-month follow-up: 60 TI, 59 NTI. Both groups have lost weight significantly (P<0.0001). 26.7% TI, and 25.4% NTI have achieved at least a 5% weight-loss (P=0.88). 81 participants have completed 6-month follow-up: 41 TI, 40 NTI. Both groups have lost weight significantly (P< 0.0001). 46.3% TI, and 32.5% NTI have achieved at least a 5% weight-loss (P=0.20). Both groups have achieved a reduction in HbA1c levels (P<0.0001), TI −0.81±1.9% and NTI −1.36±2.2% (P=0.24).
Conclusion: Our study population is mostly composed of highly educated females who report a high frequency of anxiety towards food and eating. PREDIRCAM2 shows to be a promising tool for obesity treatment and cardio-metabolic-risk prevention.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more